First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

While layoffs have slowed in the second half of the year, according to BioSpace data, companies including Bayer, Bristol ...

Despite securing the industry’s first approval for familial chylomicronemia syndrome, BMO Capital Markets believes that ...

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 ...

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

For the second time this week, a Big Pharma–partnered Parkinson’s disease asset has failed in the clinic. This time it’s ...

According to the World Health Organization, GLP-1 receptor agonists are currently being used in a highly medicalized manner.

Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their ...

Following an appeal by the Danish Medicines Agency, the European Union’s drug regulator will review two new studies that have ...

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...

Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the ...